MedTrace Logo

Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain

NCT03674892 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-08-24

Study results available
· View outcomes & findings →

Summary

This study is a prospective, interventional, open-label, single arm, non-randomized trial treating 30 patients with peripheral or mixed neuropathic corneal pain at their baseline exam and following 45 days and 90 days of daily use with the TrueTear™ ITN device.

Conditions

  • Cornea

Interventions

DEVICE

TrueTear™ intranasal neurostimulator (ITN)

TrueTear™ intranasal neurostimulator (ITN)

Sponsors & Collaborators

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • Pedram Hamrah, MD · Tufts Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-28
Primary Completion
2022-09-09
Completion
2023-09-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03674892 on ClinicalTrials.gov